BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021

Dec 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-12-07

Reporting Person: Babu Yarlagadda S (Chief Discovery Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-07	Common Stock	M	62000	$4.73	Acquired	245156	Direct
2021-12-07	Common Stock	S	30100	$12.20	Disposed	215056	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-07	Emp. Stock Option (Right to Buy)	$4.73	M	62000	Disposed	2022-03-01	Common Stock (62000)	Direct

Footnotes

F1: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.18 to $12.22. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.